Parvovirus-B19-Infektionen bei Hämophilen

  • A. Grosse-Bley
  • A. M. Eis-Hübinger
  • R. Kaiser
  • J. Oldenburg
  • H.-H. Brackmann
  • T. F. Schwarz
  • K. E. Schneweis
Conference paper

Zusammenfassung

Es ist anzunehmen, daß das humane Parvovirus-B19 (PV-B19) aufgrund seiner hohen Resistenz gegenüber Umwelteinflüssen sowie seiner hochgradigen Virämie bei Infizierten (1011-1014 Genomkopien/ml Serum) zu den Viren gezählt werden muß, die mit Gerinnungsfaktorpräparaten übertragen werden können [1].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Frickhofen N, Young NS (1991) A rapid method of sample preparation for detection of DNA viruses in human serum by polymerase chain reaction. I Virol Methods 35:65–72CrossRefGoogle Scholar
  2. 2.
    Schwarz TF, Jäger G, Holzgreve W, Roggendorf M (1992) Diagnosis of human parvovirus B 19 infection by polymerase chain reaction. Scand J Infect Dis 24:691–696PubMedCrossRefGoogle Scholar
  3. 3.
    Kwok S, Higuchi R (1989) Avoiding false positives with PCR. Nature 339:237–238PubMedCrossRefGoogle Scholar
  4. 4.
    Bowman CA, Cohen BJ, Norfolk DR, Lacey CJN (1990) Red cell aplasia associated with human parvovirus B 19 and HIV infection: failure to respond clinically to intravenous immunoglobulin. AIDS 4:1038–1039PubMedCrossRefGoogle Scholar
  5. 5.
    Nigro G, Luzi G, Fridell E, Ferrara M, Pisano P, Gattinara GC, Mezzaroma I, Söderlund M, Rasnoveanu D, Aiuti F (1992) Parvovirus infection in children with AIDS: high prevalence of B 19-specific immunoglobulin M and G antibodies. AIDS 6:679–684PubMedCrossRefGoogle Scholar
  6. 6.
    Cohen BJ, Field AM, Gudnadottir S, Beard S, Barbara JAJ (1990) Blood donor screening for parvovirus B 19. J Virol Methods 30:233–238PubMedCrossRefGoogle Scholar
  7. 7.
    McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P (1993) Detection of parvovirus B 19 in donated blood: a model system for screening by polymerase chain reaction. J Med Virol J Clin Microbiol 31:323–328Google Scholar
  8. 8.
    Lyon DJ, Chapman CS, Martin C, Brown KE, Clewley JP, Flower AJE, Mitchell VE (1989) Symptomatic parvovirus B 19 infection and heat-treated factor IX concentrate. Lancet i: 1085CrossRefGoogle Scholar
  9. 9.
    Morfini M, Longo G, Rossi Ferrini P, Azzi A, Zakrewska C, Ciappi S, Kolumban P (1992) Hypoplastic anaemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B 19 parvovirus. Am J Hematol 39:149–150PubMedCrossRefGoogle Scholar
  10. 10.
    Rollag H, Patou G, Pattison JR, Degré M, Evensen SA, Fröland SS, Glomstein A (1991) Prevalence of antibodies against parvovirus B 19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 23:675–679PubMedCrossRefGoogle Scholar
  11. 11.
    Williams MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FGH (1990) Transmission of human parvovirus B 19 by coagulation factor concentrates. Vox Sang 58:177–181PubMedCrossRefGoogle Scholar
  12. 12.
    Schwarz TF, Roggendorf M, Hottenträger B, Stolz W, Schwinn H (1991) Removal of parvovirus B 19 from contaminated factor VIII during fractionation. J Med Virol 35:28–31PubMedCrossRefGoogle Scholar
  13. 13.
    Zakrzewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR (1992) Human parvovirus B 19 in clotting factor concentrates: B 19 DNA detection by the nested polymerase chain reaction. Br J Haematol 81:407–412PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • A. Grosse-Bley
  • A. M. Eis-Hübinger
  • R. Kaiser
  • J. Oldenburg
  • H.-H. Brackmann
  • T. F. Schwarz
  • K. E. Schneweis

There are no affiliations available

Personalised recommendations